2020年11月19日07:00 GMT
报告支持Calquence在套细胞淋巴瘤中的长期随访疗效和耐受性，并汇集了慢性淋巴细胞白血病的安全性数据
新兴的管道显示出治疗耐药和侵袭性血癌的新靶点和机制的希望
澳门在线赌城娱乐将在第62届美国血液学会(ASH)年会上展示一项新的研究，旨在解决血癌患者面临的关键未满足需求, held virtually from 5 to 8 December 2020.
该公司将提交27份摘要，涵盖5种药物和潜在新药以及8种不同的血液病，表明该公司致力于推进血液病恶性肿瘤患者的血液病研究和治疗.
Key data presentations include:
- A pooled analysis of data from four trials - ELEVATE TN, 提升, ACE-CL-001 and 15-H-0016 - expanding on the cardiovascular safety profile of Calquence monotherapy treatment for patients with chronic lymphocytic leukaemia (CLL)
- Extended follow-up data from the pivotal Phase II ACE-LY-004 trial that support long-term treatment with Calquence in adult patients with relapsed or refractory mantle cell lymphoma (制程)
- 上的数据 Calquence in combination with venetoclax and either obinutuzumab or rituximab in patients with CLL, 在中位随访26年后，显示出与先前试验一致的安全性，具有高完全缓解和无法检测到的最小残留疾病率.9 months, with minimal to no drug-drug interactions in the Phase Ib ACE-CL-003 trial
- 来自潜在新药b细胞成熟抗原(BCMA)靶向抗体药物偶联物的首次人体数据, MEDI2228, presenting data on safety and efficacy at all dose levels in relapsed or refractory multiple myeloma
- 数据显示，临床前证据表明，BCL2/XL双抑制剂可克服复发或难治性制程的耐药, AZD4320, which blocks the anti-apoptotic effect of BCL2 and BCLXL
- Phase I data from the anti-inducible co-stimulator anti-ICOS monoclonal antibody, 读出- 570, 在低风险难治性和大量预处理的血管免疫母细胞t细胞淋巴瘤患者中显示出有希望的早期临床活性
- Multiple studies on roxadustat, 这是首个在CKD患者群体透析依赖性和非透析依赖性贫血中评估其临床有效性和安全性的新型药物
- 无论基线因素如何，罗沙司他对低风险骨髓增生异常综合征(MDS)继发贫血的疗效评估数据. In approximately one in three patients MDS leads to acute myeloid leukaemia.1
戴夫Fredrickson, 执行副总裁, 肿瘤事业部, said: “Our data at ASH this year continue to support Calquence as a well-tolerated treatment with impressive efficacy and safety across multiple blood cancers, reinforcing physicians’ confidence in treating patients with Calquence 从长远来看. Data at the meeting will also explore Calquence combinations with commonly used therapies, 在慢性淋巴细胞白血病的各种方案中显示出潜力，以最佳地适应每个患者的独特需求.”
José Baselga, 执行副总裁, 肿瘤学 R&D, said: “As we rapidly expand our presence in haematology, 澳门第一赌城在线娱乐的重点是确定新的靶点和作用机制，以解决各种血液系统恶性肿瘤中最紧迫的未满足需求. 澳门第一赌城在线娱乐在今年ASH的早期产品组合清楚地表明，澳门第一赌城在线娱乐致力于在对抗治疗耐药和罕见血癌方面遵循科学.”
Key 澳门在线赌城娱乐 presentations during the 62nd ASH Annual Meeting and Exposition
Calquence
Calquence (acalabrutinib) is a next-generation, selective inhibitor of Bruton’s tyrosine kinase (BTK). Calquence binds covalently to BTK, t在这里by inhibiting its activity.2,3 在b细胞, BTK signalling results in activation of pathways necessary for B-cell proliferation, 人口贩卖, 趋化性, 和附着力.2
As part of an extensive clinical development programme, 澳门在线赌城娱乐 and Acerta Pharma are currently evaluating Calquence in more than 20 company-sponsored clinical trials. Calquence is being developed for the treatment of multiple B-cell blood cancers including CLL, 制程, 弥漫大b细胞淋巴瘤, Waldenström macroglobulinaemia, 滤泡淋巴瘤, and other haematologic malignancies.
Roxadustat
Roxadustat is a first-in-class oral small molecule hypoxia-inducible-factor prolyl hydroxylase inhibitor (HIF-PHI) that promotes erythropoiesis through increased endogenous production of erythropoietin; improved iron absorption, transport and mobilisation; and downregulation of hepcidin, 哪些有助于克服炎症对血红蛋白合成和红细胞生成的负面影响. Roxadustat is approved in China for the treatment of anaemia in adult patients with CKD, both on dialysis and not on dialysis. 在日本, roxadustat is approved for the treatment of anaemia in CKD patients on dialysis, 用于治疗非透析CKD患者贫血的补充新药申请(NDA)正在监管审查中. roxadustat用于治疗NDD和DD的CKD贫血的NDA正在接受美国食品和药物管理局的审查，预计将于2020年第四季度做出决定. roxadustat用于治疗NDD和DD的CKD贫血的上市许可申请由安斯泰来提交，并于2020年5月21日被欧洲药品管理局接受审查. 罗沙司他也在临床开发与MDS相关的贫血和化疗引起的贫血.
澳门在线赌城娱乐和纤维原公司. (FibroGen)正在美国合作开发和商业化roxadustat，用于潜在的贫血治疗, China and other markets in the Americas and in Australia/New Zealand, 以及东南亚. 安斯泰来和FibroGen正在合作开发和商业化roxadustat，用于包括日本在内的地区的潜在贫血治疗, 欧洲, the Commonwealth of Independent States, the Middle East and South Africa.
澳门在线赌城娱乐在血液学
Leveraging its strength in oncology, 澳门在线赌城娱乐 has established haematology as one of four key oncology disease areas of focus. 该公司的血液学专营权包括两种获得美国食品和药物管理局批准的药物，以及一个强大的全球开发计划，用于广泛的潜在血癌治疗组合. Acerta Pharma serves as 澳门在线赌城娱乐’s haematology research and development arm. 澳门在线赌城娱乐与志同道合的科学公司合作，推动疗法的发现和开发，以解决未满足的需求.
澳门在线赌城娱乐在肿瘤学
澳门在线赌城娱乐在肿瘤学领域有着深厚的传统，并提供快速增长的新药组合，这些新药有可能改变患者的生活和公司的未来. With seven new medicines launched between 2014 and 2020, and a broad pipeline of small molecules and biologics in development, the Company is committed to advance oncology as a key growth driver for 澳门在线赌城娱乐 focused on lung, 卵巢, 乳腺癌和血癌.
By harnessing the power of six scientific platforms - Immuno-肿瘤学, 肿瘤驱动因素和耐药性, DNA损伤反应, 抗体药物偶联物, 表观遗传学, and Cell Therapies - and by championing the development of personalised combinations, 澳门在线赌城娱乐的愿景是重新定义癌症治疗，并有一天消除癌症这一死亡原因.
澳门在线赌城娱乐
澳门在线赌城娱乐 (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - 肿瘤学, 心血管, 肾 & 新陈代谢和呼吸 & 免疫学. 总部设在剑桥, UK, 澳门在线赌城娱乐在100多个国家开展业务，其创新药物被全球数百万患者使用. 请访问 澳门在线赌城娱乐.com and follow the Company on 推特 @澳门在线赌城娱乐.
联系人
For details on how to contact the 投资者关系 Team, please click 在这里. 对于“媒体联系人”，单击 在这里.
参考文献
1. 美国癌症协会. What Are Myelodysplastic Syndromes? 网上. 2020年10月.
2. Calquence (acalabrutinib) [prescribing information]. Wilmington, DE; 澳门在线赌城娱乐 Pharmaceuticals LP; 2019.
3. 吴杰，张敏 & 刘D. Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor. [J]血液学. 2016;9(21).
艾德里安·坎普
公司秘书
澳门在线赌城娱乐